We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Vectivbio Holding Ag
1 own
1 watching
Current Price
$8.48
$0.28
(3.41%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
180.61M
52-Week High
9.29
52-Week Low
2.7426
Average Volume
0M
Dividend Yield
--
P/E Ratio
--
Market Capitalization180.61M
52-Week High9.29
52-Week Low2.7426
Average Volume0M
Dividend Yield--
P/E Ratio--
What does the Vectivbio Holding Ag do?
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Read More
News & Events about Vectivbio Holding Ag.
Globe Newswire
18days ago
BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive ...
Globe Newswire
1month ago
BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the date of the Extraordinary General Meeting, which will be held...
Globe Newswire
5 months ago
Combined Gross Proceeds from Public Offering and Private Sale Total $50 MillionBASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, ...
Globe Newswire
5 months ago
Interim proof-of-concept data anticipated from STARGAZE in H1 2023 First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease Second clinical indication under evaluation for apraglutide, demonstrating broad potential of this next generation GLP-2 analog ...
Globe Newswire
1 year ago
-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- -Expanded Rare Disease Pipeline with the Acquisition of CoMET Small Molecule Platform for Inherited Metabolic Diseases (IMDs)- -IND ...
Frequently Asked Questions
Frequently Asked Questions
What is Vectivbio Holding Ag share price today?
plus_minus_icon
Can Indians buy Vectivbio Holding Ag shares?
plus_minus_icon
How can I buy Vectivbio Holding Ag shares from India?
plus_minus_icon
Can Fractional shares of Vectivbio Holding Ag be purchased?
plus_minus_icon
What are the documents required to start investing in Vectivbio Holding Ag stocks?
plus_minus_icon
What is today’s traded volume of Vectivbio Holding Ag?
plus_minus_icon
What is today’s market capitalisation of Vectivbio Holding Ag?
plus_minus_icon
What is the 52-Week High and Low Range of Vectivbio Holding Ag?
plus_minus_icon
What percentage is Vectivbio Holding Ag down from its 52-Week High?
plus_minus_icon
What percentage is Vectivbio Holding Ag up from its 52-Week Low?
plus_minus_icon
Current Price
$8.48
$0.28
(3.41%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00